Abstract
The oral adsorbent AST-120 is composed of spherical carbon particles and has an adsorption ability for certain small-molecular-weight compounds that accumulate in patients with chronic kidney disease (CKD). So far, very few compounds are known to be adsorbed by AST-120 in vivo. To examine the effect of AST-120 in vivo, we comprehensively evaluated the plasma concentrations of 146 compounds (61 anions and 85 cations) in CKD model rats, with or without four weeks of treatment with AST-120. By capillary electrophoresis with mass spectrometry, we identified 6 anions and 17 cations that were significantly decreased by AST-120 treatment. In contrast, we also identified 2 cations that were significantly increased by AST-120. Among them, 4 anions, apart from indoxyl sulfate and hippurate, and 19 cations were newly identified in this study. The plasma levels of N-acetyl-neuraminate, 4-pyridoxate, 4-oxopentanoate, glycine, γ-guanidinobutyrate, N-γ-ethylglutamine, allantoin, cytosine, 5-methylcytosine and imidazole-4-acetate were significantly increased in the CKD model compared with the sham-operated group, and were significantly decreased by AST-120 treatment. Therefore, these 10 compounds could be added as uremic compounds that indicate the effect of AST-120 treatment. This study provides useful information not only for identifying the indicators of AST-120, but also for clarifying changes in the metabolic profile by AST-120 treatment in the clinical setting.
| Original language | English |
|---|---|
| Pages (from-to) | 1309-1322 |
| Number of pages | 14 |
| Journal | Toxins |
| Volume | 4 |
| Issue number | 11 |
| DOIs | |
| Publication status | Published - 2012 Nov |
Fingerprint
Keywords
- AST-120
- CE-MS
- Uremic toxin
ASJC Scopus subject areas
- Toxicology
- Health, Toxicology and Mutagenesis
Cite this
A Metabolomic approach to clarifying the effect of AST-120 on 5/6 nephrectomized rats by capillary electrophoresis with mass spectrometry (CE-MS). / Akiyama, Yasutoshi; Takeuchi, Yoichi; Kikuchi, Koichi; Mishima, Eikan; Yamamoto, Yasuaki; Suzuki, Chitose; Toyohara, Takafumi; Suzuki, Takehiro; Hozawa, Atsushi; Ito, Sadayoshi; Soga, Tomoyoshi; Abe, Takaaki.
In: Toxins, Vol. 4, No. 11, 11.2012, p. 1309-1322.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - A Metabolomic approach to clarifying the effect of AST-120 on 5/6 nephrectomized rats by capillary electrophoresis with mass spectrometry (CE-MS)
AU - Akiyama, Yasutoshi
AU - Takeuchi, Yoichi
AU - Kikuchi, Koichi
AU - Mishima, Eikan
AU - Yamamoto, Yasuaki
AU - Suzuki, Chitose
AU - Toyohara, Takafumi
AU - Suzuki, Takehiro
AU - Hozawa, Atsushi
AU - Ito, Sadayoshi
AU - Soga, Tomoyoshi
AU - Abe, Takaaki
PY - 2012/11
Y1 - 2012/11
N2 - The oral adsorbent AST-120 is composed of spherical carbon particles and has an adsorption ability for certain small-molecular-weight compounds that accumulate in patients with chronic kidney disease (CKD). So far, very few compounds are known to be adsorbed by AST-120 in vivo. To examine the effect of AST-120 in vivo, we comprehensively evaluated the plasma concentrations of 146 compounds (61 anions and 85 cations) in CKD model rats, with or without four weeks of treatment with AST-120. By capillary electrophoresis with mass spectrometry, we identified 6 anions and 17 cations that were significantly decreased by AST-120 treatment. In contrast, we also identified 2 cations that were significantly increased by AST-120. Among them, 4 anions, apart from indoxyl sulfate and hippurate, and 19 cations were newly identified in this study. The plasma levels of N-acetyl-neuraminate, 4-pyridoxate, 4-oxopentanoate, glycine, γ-guanidinobutyrate, N-γ-ethylglutamine, allantoin, cytosine, 5-methylcytosine and imidazole-4-acetate were significantly increased in the CKD model compared with the sham-operated group, and were significantly decreased by AST-120 treatment. Therefore, these 10 compounds could be added as uremic compounds that indicate the effect of AST-120 treatment. This study provides useful information not only for identifying the indicators of AST-120, but also for clarifying changes in the metabolic profile by AST-120 treatment in the clinical setting.
AB - The oral adsorbent AST-120 is composed of spherical carbon particles and has an adsorption ability for certain small-molecular-weight compounds that accumulate in patients with chronic kidney disease (CKD). So far, very few compounds are known to be adsorbed by AST-120 in vivo. To examine the effect of AST-120 in vivo, we comprehensively evaluated the plasma concentrations of 146 compounds (61 anions and 85 cations) in CKD model rats, with or without four weeks of treatment with AST-120. By capillary electrophoresis with mass spectrometry, we identified 6 anions and 17 cations that were significantly decreased by AST-120 treatment. In contrast, we also identified 2 cations that were significantly increased by AST-120. Among them, 4 anions, apart from indoxyl sulfate and hippurate, and 19 cations were newly identified in this study. The plasma levels of N-acetyl-neuraminate, 4-pyridoxate, 4-oxopentanoate, glycine, γ-guanidinobutyrate, N-γ-ethylglutamine, allantoin, cytosine, 5-methylcytosine and imidazole-4-acetate were significantly increased in the CKD model compared with the sham-operated group, and were significantly decreased by AST-120 treatment. Therefore, these 10 compounds could be added as uremic compounds that indicate the effect of AST-120 treatment. This study provides useful information not only for identifying the indicators of AST-120, but also for clarifying changes in the metabolic profile by AST-120 treatment in the clinical setting.
KW - AST-120
KW - CE-MS
KW - Uremic toxin
UR - http://www.scopus.com/inward/record.url?scp=84870563668&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84870563668&partnerID=8YFLogxK
U2 - 10.3390/toxins4111309
DO - 10.3390/toxins4111309
M3 - Article
C2 - 23202318
AN - SCOPUS:84870563668
VL - 4
SP - 1309
EP - 1322
JO - Toxins
JF - Toxins
SN - 2072-6651
IS - 11
ER -